Patents-Review.com
🔗 Permalink
Assignee profile:

Arrowhead Pharmaceuticals, Inc.

City:

Pasadena, California

Country:

United States

Published Applications:

108

Last publication date:

2025-10-02

Patent Grants:

100

Last grant date:

2026-02-17

Top Inventors for applications by Arrowhead Pharmaceuticals, Inc.

These are the the leading inventors for applications assigned to Arrowhead Pharmaceuticals, Inc.:

Recent patent applications by Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. based in Pasadena, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2025-10-02 ✅ Patent 12,551,569 granted on 2026-02-17
US20250302980A1
Human necessities

RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use

 #2 | 2025-07-24 ✅ Patent 12,527,877 granted on 2026-01-20
US20250235549A1
Human necessities

ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOF

 #3 | 2025-07-03 ✅ Patent 12,378,558 granted on 2025-08-05
US20250215433A1
Chemistry; metallurgy

RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use

 #4 | 2025-06-26 ✅ Patent 12,442,002 granted on 2025-10-14
US20250207139A1
Chemistry; metallurgy

RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use

 #5 | 2025-06-19
US20250197861A1
Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF ALPHA-1 ANTITRYPSIN

 #6 | 2025-04-10
US20250115907A1
Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA

 #7 | 2025-03-06 ✅ Patent 12,503,696 granted on 2025-12-23
US20250075214A1
Chemistry; metallurgy

RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Use

 #8 | 2024-05-23 ✅ Patent 12,110,492 granted on 2024-10-08
US20240167035A1
Chemistry; metallurgy

RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use

 #9 | 2024-05-02
US20240141351A1
Chemistry; metallurgy

ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE

 #10 | 2024-01-25 ✅ Patent 11,912,997 granted on 2024-02-27
US20240026363A1
Chemistry; metallurgy

RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use

 #11 | 2023-11-09
US20230355654A1
Human necessities

RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION

 #12 | 2023-11-09
US20230355651A1
Human necessities

RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION

 #13 | 2023-11-02
US20230348905A1
Chemistry; metallurgy

METHODS FOR THE REDUCTION OF Z-AAT PROTEIN LEVELS

 #14 | 2023-10-12 ✅ Patent 12,365,899 granted on 2025-07-22
US20230323350A1
Chemistry; metallurgy

RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)

 #15 | 2023-08-24 ✅ Patent 11,845,937 granted on 2023-12-19
US20230265430A1
Chemistry; metallurgy

RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

 #16 | 2023-04-27 ✅ Patent 12,630,826 granted on 2026-05-19
US20230125671A1
Chemistry; metallurgy

RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use

 #17 | 2023-01-19 ✅ Patent 11,629,349 granted on 2023-04-18
US20230013224A1
Chemistry; metallurgy

RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

 #18 | 2023-01-05 ✅ Patent 11,549,112 granted on 2023-01-10
US20230002773A1
Chemistry; metallurgy

RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

 #19 | 2023-01-05 ✅ Patent 12,188,017 granted on 2025-01-07
US20230002768A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin

 #20 | 2023-01-05 ✅ Patent 12,365,897 granted on 2025-07-22
US20230002767A1
Chemistry; metallurgy

RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use

 #21 | 2022-12-22 ✅ Patent 12,065,458 granted on 2024-08-20
US20220402947A1
Chemistry; metallurgy

Trialkyne linking agents and methods of use

 #22 | 2022-12-15 ✅ Patent 12,486,502 granted on 2025-12-02
US20220396791A1
Chemistry; metallurgy

RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use

 #23 | 2022-12-01 ✅ Patent 12,091,661 granted on 2024-09-17
US20220380775A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #24 | 2022-09-29 ✅ Patent 12,582,668 granted on 2026-03-24
US20220305046A1
Human necessities

METHODS FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)

 #25 | 2022-06-30 ✅ Patent 12,221,610 granted on 2025-02-11
US20220204976A1
Chemistry; metallurgy

RNAi agents for inhibiting expression of HIF-2 alpha (), compositions thereof, and methods of use

 #26 | 2022-06-02 ✅ Patent 11,884,920 granted on 2024-01-30
US20220170015A1
Chemistry; metallurgy

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

 #27 | 2022-04-21 ✅ Patent 12,441,756 granted on 2025-10-14
US20220119439A1
Chemistry; metallurgy

5'-Cyclo-Phosphonate Modified Nucleotides

 #28 | 2022-03-17 ✅ Patent 11,517,584 granted on 2022-12-06
US20220079973A1
Human necessities

RNAi agents for Hepatitis B virus infection

 #29 | 2022-02-24 ✅ Patent 12,534,728 granted on 2026-01-27
US20220056454A1
Chemistry; metallurgy

RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use

 #30 | 2022-01-27 ✅ Patent 12,173,086 granted on 2024-12-24
US20220024975A1
Chemistry; metallurgy

Alpha-v beta-6 integrin ligands and uses thereof

 #31 | 2021-12-23
US20210395745A1
Chemistry; metallurgy

RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION

 #32 | 2021-09-30 ✅ Patent 12,054,718 granted on 2024-08-06
US20210301294A1
Chemistry; metallurgy

RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use

 #33 | 2021-06-24 ✅ Patent 12,116,573 granted on 2024-10-15
US20210189394A1
Chemistry; metallurgy

Targeting ligands for therapeutic compounds

 #34 | 2021-06-17 ✅ Patent 11,840,688 granted on 2023-12-12
US20210180066A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of Hif2alpha

 #35 | 2021-04-08 ✅ Patent 11,590,156 granted on 2023-02-28
US20210100829A1
Human necessities

RNAi agents for hepatitis B virus infection

 #36 | 2021-03-11 ✅ Patent 12,582,718 granted on 2026-03-24
US20210069337A1
Human necessities

INTEGRIN TARGETING LIGANDS AND USES THEREOF

 #37 | 2021-02-25 ✅ Patent 11,534,453 granted on 2022-12-27
US20210052624A1
Human necessities

RNAi therapy for hepatitis B virus infection

 #38 | 2020-11-26 ✅ Patent 11,597,701 granted on 2023-03-07
US20200369613A1
Chemistry; metallurgy

Integrin ligands and uses thereof

 #39 | 2020-09-24 ✅ Patent 11,214,802 granted on 2022-01-04
US20200299691A1
Chemistry; metallurgy

RNAi agents for inhibiting expression of alpha-ENaC and methods of use

 #40 | 2020-09-24 ✅ Patent 11,214,801 granted on 2022-01-04
US20200299690A1
Chemistry; metallurgy

RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

 #41 | 2020-09-03 ✅ Patent 11,920,134 granted on 2024-03-05
US20200277610A1
Chemistry; metallurgy

Compositions and methods for inhibiting expression of RRM2 genes

 #42 | 2020-07-02 ✅ Patent 11,203,756 granted on 2021-12-21
US20200208149A1
Chemistry; metallurgy

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

 #43 | 2020-06-18 ✅ Patent 11,261,444 granted on 2022-03-01
US20200190517A1
Chemistry; metallurgy

Organic compositions to treat EPAS1-related diseases

 #44 | 2020-05-21 ✅ Patent 11,208,662 granted on 2021-12-28
US20200157550A1
Chemistry; metallurgy

RNAi inhibition of alpha-ENaC expression

 #45 | 2019-11-28 ✅ Patent 10,858,658 granted on 2020-12-08
US20190359984A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of factor XII

 #46 | 2019-09-26 ✅ Patent 10,780,108 granted on 2020-09-22
US20190292547A1
Chemistry; metallurgy

RNAi agents for Hepatitis B virus infection

 #47 | 2019-09-19 ✅ Patent 11,384,355 granted on 2022-07-12
US20190284558A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

 #48 | 2019-09-12 ✅ Patent 11,091,761 granted on 2021-08-17
US20190276827A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #49 | 2019-08-22 ✅ Patent 11,174,481 granted on 2021-11-16
US20190256849A1
Chemistry; metallurgy

Targeting ligands

 #50 | 2019-08-22
US20190255091A1
Human necessities

RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

 #51 | 2019-08-15 ✅ Patent 11,180,529 granted on 2021-11-23
US20190248832A1
Chemistry; metallurgy

Alpha-v beta-6 integrin ligands and uses thereof

 #52 | 2019-08-01 ✅ Patent 11,066,667 granted on 2021-07-20
US20190233817A1
Chemistry; metallurgy

Organic compositions to treat APOC3-related diseases

 #53 | 2019-03-21 ✅ Patent 11,078,227 granted on 2021-08-03
US20190085012A1
Chemistry; metallurgy

5′-cyclo-phosphonate modified nucleotides

 #54 | 2019-03-14 ✅ Patent 10,995,335 granted on 2021-05-04
US20190078089A1
Chemistry; metallurgy

RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use

 #55 | 2019-03-14 ✅ Patent 10,597,657 granted on 2020-03-24
US20190078088A1
Chemistry; metallurgy

RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

 #56 | 2019-01-24 ✅ Patent 10,806,750 granted on 2020-10-20
US20190022123A1
Human necessities

RNAi therapy for hepatitis B virus infection

 #57 | 2019-01-10 ✅ Patent 10,590,416 granted on 2020-03-17
US20190010494A1
Chemistry; metallurgy

RNAi agents for inhibiting expression of alpha-ENaC and methods of use

 #58 | 2018-12-13 ✅ Patent 10,550,391 granted on 2020-02-04
US20180355362A1
Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

 #59 | 2018-08-16 ✅ Patent 10,927,373 granted on 2021-02-23
US20180230470A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of Hif2alpha

 #60 | 2018-07-12 ✅ Patent 10,619,160 granted on 2020-04-14
US20180195074A1
Chemistry; metallurgy

Compositions and methods for inhibiting expression of RRM2 genes

 #61 | 2018-07-12 ✅ Patent 10,662,427 granted on 2020-05-26
US20180195070A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of LPA

 #62 | 2018-07-12 ✅ Patent 10,450,565 granted on 2019-10-22
US20180195069A1
Chemistry; metallurgy

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

 #63 | 2018-05-31 ✅ Patent 10,544,418 granted on 2020-01-28
US20180148726A1
Chemistry; metallurgy

RNAi inhibition of alpha-ENaC expression

 #64 | 2018-04-12 ✅ Patent 10,538,765 granted on 2020-01-21
US20180100151A1
Chemistry; metallurgy

Organic compositions to treat EPAS1-related diseases

 #65 | 2018-03-08 ✅ Patent 10,294,474 granted on 2019-05-21
US20180064819A1
Human necessities

Targeting ligands

 #66 | 2018-01-25 ✅ Patent 10,308,941 granted on 2019-06-04
US20180023086A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of factor XII

 #67 | 2018-01-25 ✅ Patent 10,047,361 granted on 2018-08-14
US20180023084A1
Chemistry; metallurgy

Disulfide-containing alkyne linking agents

 #68 | 2017-11-16 ✅ Patent 10,081,811 granted on 2018-09-25
US20170327829A1
Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

 #69 | 2017-10-19 ✅ Patent 10,329,563 granted on 2019-06-25
US20170298354A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #70 | 2017-09-07 ✅ Patent 10,246,709 granted on 2019-04-02
US20170253875A1
Chemistry; metallurgy

Targeting ligands for therapeutic compounds

 #71 | 2017-07-20 ✅ Patent 10,273,482 granted on 2019-04-30
US20170204417A1
Chemistry; metallurgy

dsRNA for treating viral infection

 #72 | 2017-05-25 ✅ Patent 10,138,483 granted on 2018-11-27
US20170145415A1
Chemistry; metallurgy

Transferrin/transferrin receptor-mediated siRNA delivery

 #73 | 2017-05-18 ✅ Patent 9,938,531 granted on 2018-04-10
US20170137827A1
Chemistry; metallurgy

Compositions and methods for inhibiting expression of RRM2 genes

 #74 | 2017-05-18 ✅ Patent 10,240,153 granted on 2019-03-26
US20170137814A1
Chemistry; metallurgy

Organic compositions to treat APOC3-related diseases

 #75 | 2017-04-06 ✅ Patent 9,932,586 granted on 2018-04-03
US20170096665A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of LPA

 #76 | 2017-03-16 ✅ Patent 10,287,582 granted on 2019-05-14
US20170073678A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #77 | 2017-02-23 ✅ Patent 9,765,340 granted on 2017-09-19
US20170051291A1
Chemistry; metallurgy

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders

 #78 | 2017-02-09 ✅ Patent 10,130,651 granted on 2018-11-20
US20170035796A1
Human necessities

RNAi Therapy for Hepatitis B Virus Infection

 #79 | 2017-01-12 ✅ Patent 9,752,147 granted on 2017-09-05
US20170009235A1
Chemistry; metallurgy

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

 #80 | 2016-12-29 ✅ Patent 9,914,927 granted on 2018-03-13
US20160376599A1
Chemistry; metallurgy

RNAi inhibition of alpha-ENaC expression

 #81 | 2016-12-01 ✅ Patent 9,976,141 granted on 2018-05-22
US20160348107A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of Hif2alpha

 #82 | 2016-12-01 ✅ Patent 10,005,815 granted on 2018-06-26
US20160347793A1
Chemistry; metallurgy

Biologically cleavable tetrapeptide linking agents

 #83 | 2016-09-22 ✅ Patent 9,752,152 granted on 2017-09-05
US20160272979A1
Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

 #84 | 2016-09-22 ✅ Patent 9,803,205 granted on 2017-10-31
US20160272978A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of factor XII

 #85 | 2016-09-22 ✅ Patent 9,803,201 granted on 2017-10-31
US20160272971A1
Chemistry; metallurgy

Disulfide-containing alkyne linking agents

 #86 | 2016-09-22 ✅ Patent 10,059,681 granted on 2018-08-28
US20160272605A1
Chemistry; metallurgy

Disubstituted maleic anhydrides with altered kinetics of ring closure

 #87 | 2016-09-08 ✅ Patent 9,932,584 granted on 2018-04-03
US20160257956A1
Chemistry; metallurgy

Interfering RNA delivery system and uses thereof

 #88 | 2016-08-04 ✅ Patent 10,316,316 granted on 2019-06-11
US20160222384A1
Chemistry; metallurgy

Compositions for targeted delivery of siRNA

 #89 | 2016-06-02 ✅ Patent 9,526,799 granted on 2016-12-27
US20160151514A1
Human necessities

Low density lipoprotein receptor-mediated siRNA delivery

 #90 | 2016-04-14 ✅ Patent 9,796,756 granted on 2017-10-24
US20160102120A1
Chemistry; metallurgy

Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

 #91 | 2016-02-25 ✅ Patent 9,745,585 granted on 2017-08-29
US20160053270A1
Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

 #92 | 2016-01-14 ✅ Patent 9,868,949 granted on 2018-01-16
US20160010089A1
Chemistry; metallurgy

Organic compositions to treat EPAS1-related diseases

 #93 | 2016-01-07 ✅ Patent 9,476,047 granted on 2016-10-25
US20160002638A1
Chemistry; metallurgy

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

 #94 | 2015-12-17 ✅ Patent 10,006,025 granted on 2018-06-26
US20150361427A1
Chemistry; metallurgy

Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

 #95 | 2015-12-10 ✅ Patent 9,526,796 granted on 2016-12-27
US20150352221A1
Human necessities

Peptide-based in vivo siRNA delivery system

 #96 | 2015-12-03 ✅ Patent 9,422,556 granted on 2016-08-23
US20150344886A1
Chemistry; metallurgy

RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis

 #97 | 2015-11-05 ✅ Patent 9,562,230 granted on 2017-02-07
US20150315592A1
Chemistry; metallurgy

Transferrin/transferrin receptor-mediated siRNA delivery

 #98 | 2015-10-29 ✅ Patent 9,550,994 granted on 2017-01-24
US20150307882A1
Chemistry; metallurgy

RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

 #99 | 2015-10-15 ✅ Patent 10,023,862 granted on 2018-07-17
US20150291954A1
Chemistry; metallurgy

Organic compositions to treat beta-catenin-related diseases

 #100 | 2015-10-08 ✅ Patent 9,476,052 granted on 2016-10-25
US20150284726A1
Chemistry; metallurgy

RNAi inhibition of alpha-ENaC expression

Also check out Arrowhead Pharmaceuticals, Inc.'s (Pasadena, United States) applicant profile with 102 patent applications submitted.

AssigneeID:

152373 ⎘